Mereo BioPharma Group plc American Depositary Shares (MREO) is a publicly traded Healthcare sector company. As of May 21, 2026, MREO trades at $0.28 with a market cap of $37.89M and a P/E ratio of -5.44. MREO moved +20.25% today. Year to date, MREO is -41.18%; over the trailing twelve months it is -87.71%. Its 52-week range spans $0.20 to $4.72. Analyst consensus is buy with an average price target of $2.33. Rallies surfaces MREO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Mereo BioPharma Narrows Q1 Loss to $6.7M, Starts Pediatric Setrusumab Review: Mereo BioPharma reported a Q1 net loss of $6.7M versus $12.9M year-on-year, with cash of $36.2M funding operations into mid-2027. The company initiated regulatory engagement for pediatric setrusumab following Phase 3 data, is pursuing an alvelestat Phase 3 partnership, and expects vantictumab Phase 2 in H2 2026.
| Metric | Value |
|---|---|
| Price | $0.28 |
| Market Cap | $37.89M |
| P/E Ratio | -5.44 |
| EPS | $-0.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.72 |
| 52-Week Low | $0.20 |
| Volume | 12.77K |
| Avg Volume | 0 |
| Revenue (TTM) | $500.00K |
| Net Income | $-41.88M |
| Gross Margin | 0.00% |
5 analysts cover MREO: 0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.33.